| 22UA Stock | | | EUR 103.00 4.60 4.28% |
Founder
Pr MD is CoFounder Board of BioNTech SE
| Age | 79 |
| Phone | 49 6131 9084 0 |
| Web | https://www.biontech.de |
BioNTech Management Efficiency
The company has return on total asset
(ROA) of
0.4283 % which means that it generated a profit of $0.4283 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
0.7624 %, meaning that it generated $0.7624 on every $100 dollars invested by stockholders. BioNTech's management efficiency ratios could be used to measure how well BioNTech manages its routine affairs as well as how well it operates its assets and liabilities.
BioNTech SE has accumulated 171.6
M in total debt with debt to equity ratio
(D/E) of 0.05, which may suggest the company is not taking enough advantage from borrowing. BioNTech SE has a current ratio of 2.62, suggesting that it is
liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist BioNTech until it has trouble settling it off, either with new capital or with free cash flow. So, BioNTech's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like BioNTech SE sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for BioNTech to invest in growth at high rates of return. When we think about BioNTech's use of debt, we should always consider it together with cash and equity.
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany. BIONTECH operates under Biotechnology classification in Germany and is traded on Frankfurt Stock Exchange. It employs 2500 people. BioNTech SE (22UA) is traded on Frankfurt Exchange in Germany and employs 4,000 people.
Management Performance
BioNTech SE Leadership Team
Elected by the shareholders, the BioNTech's board of directors comprises two types of representatives: BioNTech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of BioNTech. The board's role is to monitor BioNTech's management team and ensure that shareholders' interests are well served. BioNTech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, BioNTech's outside directors are responsible for providing unbiased perspectives on the board's policies.
BioNTech Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is BioNTech a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in BioNTech Stock
When determining whether BioNTech SE offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioNTech's
financial statements, including income statements, balance sheets, and cash flow statements, to assess its
financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biontech Se Stock.
Outlined below are crucial reports that will aid in making a well-informed decision on Biontech Se Stock: Check out
Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNTech SE. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as
signals in nation.
You can also try the
Global Correlations module to find global opportunities by holding instruments from different markets.
Please note, there is a significant difference between BioNTech's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioNTech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioNTech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.